AU2002220559A1 - Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives - Google Patents

Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Info

Publication number
AU2002220559A1
AU2002220559A1 AU2002220559A AU2055902A AU2002220559A1 AU 2002220559 A1 AU2002220559 A1 AU 2002220559A1 AU 2002220559 A AU2002220559 A AU 2002220559A AU 2055902 A AU2055902 A AU 2055902A AU 2002220559 A1 AU2002220559 A1 AU 2002220559A1
Authority
AU
Australia
Prior art keywords
heterocyclylmethyl
quinoline
farnesyl transferase
quinazoline derivatives
transferase inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220559A
Other languages
English (en)
Inventor
Patrick Rene Angibaud
Laurence Anne Mevellec
Marc Gaston Venet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2002220559A1 publication Critical patent/AU2002220559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002220559A 2000-09-25 2001-09-18 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives Abandoned AU2002220559A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00203368 2000-09-25
EP00203368 2000-09-25
EP01202190 2001-06-07
EP01202190 2001-06-07
PCT/EP2001/010894 WO2002024686A2 (fr) 2000-09-25 2001-09-18 Derives de la quinoleine et de la quinazoline 6-heterocyclylmethyle inhibiteurs de la farnesyle transferase

Publications (1)

Publication Number Publication Date
AU2002220559A1 true AU2002220559A1 (en) 2002-04-02

Family

ID=26072730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220559A Abandoned AU2002220559A1 (en) 2000-09-25 2001-09-18 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Country Status (8)

Country Link
US (1) US7196094B2 (fr)
EP (1) EP1322650B1 (fr)
JP (1) JP4974438B2 (fr)
AT (1) ATE409189T1 (fr)
AU (1) AU2002220559A1 (fr)
DE (1) DE60135919D1 (fr)
ES (1) ES2313991T3 (fr)
WO (1) WO2002024686A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1408971A4 (fr) 2001-06-21 2006-01-25 Ariad Pharma Inc Nouvelles quinoleines et leurs utilisations
CA2478813C (fr) 2002-03-22 2011-10-18 Janssen Pharmaceutica N.V. Derives de 2-quinoleine et de 2-quinazoline substitues par du benzylimidazole utilises en tant qu'inhibiteurs de farnesyl transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
AU2004275719B2 (en) * 2003-09-23 2010-08-19 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
CA2559282A1 (fr) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
WO2005089504A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
WO2005089518A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Expression de uch-l1 et cancerotherapie
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2006017369A2 (fr) * 2004-07-13 2006-02-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Traitement d'infections virales
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
CA2634598A1 (fr) 2005-12-23 2007-07-05 Link Medicine Corporation Traitement de formes de synucleinopathie
CA2643044A1 (fr) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline et derives de quinoxaline en tant qu'inhibiteurs de phosphodiesterase 10
WO2009151683A2 (fr) * 2008-03-12 2009-12-17 Link Medicine Corporation Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2014062658A1 (fr) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle à liaison méthylène
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
EP2909193B1 (fr) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Modulateurs de ror-gamma-t de type quinolinyle à liaison phényle
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002864C (fr) 1988-11-29 1999-11-16 Eddy J. E. Freyne Derives de quinoline, quinazoline ou quinoxaline (1h-azol-1-ylmethyl) substitues
CA2231105C (fr) 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
PT988038E (pt) 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
DK1094839T3 (da) 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
EE04579B1 (et) 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
AU4925499A (en) 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
BR9913315A (pt) 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
WO2000039082A2 (fr) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. Derives de 1,2-quinoline condensee
CN1340051A (zh) 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物

Also Published As

Publication number Publication date
ATE409189T1 (de) 2008-10-15
ES2313991T3 (es) 2009-03-16
WO2002024686A2 (fr) 2002-03-28
WO2002024686A3 (fr) 2002-06-13
JP4974438B2 (ja) 2012-07-11
EP1322650A2 (fr) 2003-07-02
DE60135919D1 (de) 2008-11-06
JP2004509887A (ja) 2004-04-02
EP1322650B1 (fr) 2008-09-24
US20030207887A1 (en) 2003-11-06
US7196094B2 (en) 2007-03-27

Similar Documents

Publication Publication Date Title
AU2002220559A1 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
AU2464601A (en) Tricyclic protein kinase inhibitors
AU2001293826A1 (en) Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
HUP0104752A3 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors and pharmaceutical compositions containing them
MX9700883A (es) Derivados sustituidos de la quinazolina.
PT1442024E (pt) Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b)
IL163777A0 (en) Kinase inhibitors
AU2001241927A1 (en) Inhibitors of p38-alpha kinase
AU2002357773A1 (en) 1,6 naphthyridines useful as inhibitors of syk kinase
WO2001019828A3 (fr) Inhibiteurs de kinase utilises comme agents therapeutiques
MY130718A (en) Antitumor compounds and methods
AU2002254152A1 (en) (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
AU2001293829A1 (en) Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
WO2004063151A3 (fr) Nouveaux inhibiteurs de tyrosine kinase
AU2001293835A1 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
HK1018446A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors.
ATE319704T1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
NZ514576A (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]- naphthyridine inhibitors of tyrosine kinases
AU2003290592A1 (en) Antitumor benzoylsulfonamides
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
PT1351954E (pt) Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
AU2002254375A1 (en) Inhibitors of prenyl-protein transferase
AU2001253601A1 (en) 5-substituted tetralones as inhibitors of ras farnesyl transferase
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives